Endo International PLC (DELISTED) (ENDPQ:DL)
0.0006
0.00 (0.00%)
USD |
OTCM |
May 01, 16:00
Endo International Research and Development Expense (Quarterly): 28.14M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 28.14M |
| September 30, 2023 | 31.58M |
| June 30, 2023 | 28.04M |
| March 31, 2023 | 27.70M |
| December 31, 2022 | 30.23M |
| September 30, 2022 | 31.88M |
| June 30, 2022 | 29.79M |
| March 31, 2022 | 36.13M |
| December 31, 2021 | 38.42M |
| September 30, 2021 | 25.62M |
| June 30, 2021 | 29.67M |
| March 31, 2021 | 29.74M |
| December 31, 2020 | 31.41M |
| September 30, 2020 | 32.06M |
| June 30, 2020 | 30.50M |
| March 31, 2020 | 31.62M |
| December 31, 2019 | 34.38M |
| September 30, 2019 | 36.52M |
| June 30, 2019 | 26.35M |
| March 31, 2019 | 33.49M |
| December 31, 2018 | 25.40M |
| September 30, 2018 | 39.68M |
| June 30, 2018 | 82.10M |
| March 31, 2018 | 38.65M |
| December 31, 2017 | 48.54M |
| Date | Value |
|---|---|
| September 30, 2017 | 39.64M |
| June 30, 2017 | 40.87M |
| March 31, 2017 | 43.01M |
| December 31, 2016 | 46.21M |
| September 30, 2016 | 44.88M |
| June 30, 2016 | 50.59M |
| March 31, 2016 | 41.69M |
| December 31, 2015 | 43.99M |
| September 30, 2015 | 21.33M |
| June 30, 2015 | 18.98M |
| March 31, 2015 | 17.90M |
| December 31, 2014 | 30.54M |
| September 30, 2014 | 20.81M |
| June 30, 2014 | 30.41M |
| March 31, 2014 | 30.95M |
| December 31, 2013 | -11.38M |
| September 30, 2013 | 36.69M |
| June 30, 2013 | 33.39M |
| March 31, 2013 | 38.77M |
| December 31, 2012 | 36.07M |
| September 30, 2012 | 48.95M |
| June 30, 2012 | 45.43M |
| March 31, 2012 | 88.69M |
| December 31, 2011 | 52.98M |
| September 30, 2011 | 43.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
25.62M
Minimum
Sep 2021
38.42M
Maximum
Dec 2021
31.04M
Average
30.50M
Median
Jun 2020
Research and Development Expense (Quarterly) Benchmarks
| Alkermes PLC | 67.61M |
| Jazz Pharmaceuticals PLC | 222.85M |
| Medtronic PLC | 695.00M |
| Perrigo Co PLC | 29.00M |
| Iterum Therapeutics PLC | 3.977M |